Concentrated Pharma ETF Outperforms but Carries Bigger Single-Stock Risk

Overview

• The VanEck Pharmaceutical ETF (PPH) has outpaced the iShares Global Healthcare ETF (IXJ) over the trailing 12 months and five-year span, with PPH showing roughly 20.4% one-year total return versus about 10.0% for IXJ and stronger five-year growth.
• PPH is a narrow, pure-play fund that tracks the MVIS US Listed Pharmaceutical 25 Index, holds about 26 positions and places roughly 21% in Eli Lilly, which raises single-stock and sub-sector risk for holders.
• IXJ offers a broad global healthcare mix across drugs, biotech and equipment with about 114 holdings, much larger assets under management near $3.6 billion, and smaller top weights such as Eli Lilly around 10.5%, which supports greater diversification and liquidity.
• Costs and payouts differ only modestly: PPH carries a slightly lower expense ratio at 0.36% versus IXJ's 0.40% and a higher trailing dividend yield (about 2.10% for PPH versus 1.50% for IXJ), but PPH has a larger five-year max drawdown in recent metrics.
• Both fund types share the same long-term sector drivers—aging populations, drug innovation and medical technology growth—while facing common risks like patent expirations, regulatory action and pricing pressure that can cause volatility and idiosyncratic hits to concentrated holdings.